NCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
3 trialsNCT03670069 2024-05-08
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03272464 2023-09-22
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
Phase 1 Terminated